These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27642668)

  • 1. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.
    Chan KR; Wang X; Saron WAA; Gan ES; Tan HC; Mok DZL; Zhang SL; Lee YH; Liang C; Wijaya L; Ghosh S; Cheung YB; Tannenbaum SR; Abraham SN; St John AL; Low JGH; Ooi EE
    Nat Microbiol; 2016 Sep; 1(12):16164. PubMed ID: 27642668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial.
    Low JG; Wijaya L; Li GK; Lim EY; Shum AK; Cheung YB; Ooi EE
    Trials; 2015 Apr; 16():147. PubMed ID: 25872531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
    Taga K; Imura S; Hayashi A; Kamakura K; Hashimoto S; Takasaki T; Kurane I; Uchida Y
    Kansenshogaku Zasshi; 2002 Sep; 76(9):738-46. PubMed ID: 12391677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
    Monath TP; Craven RB; Muth DJ; Trautt CJ; Calisher CH; Fitzgerald SA
    Am J Trop Med Hyg; 1980 Jul; 29(4):624-34. PubMed ID: 7406113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
    Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
    Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F
    Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine.
    Kayser M; Klein H; Paasch I; Pilaski J; Blenk H; Heeg K
    J Med Virol; 1985 Sep; 17(1):35-45. PubMed ID: 2995571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
    Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
    Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine.
    Eckels KH; Kliks SC; Dubois DR; Wahl LM; Bancroft WH
    J Immunol; 1985 Dec; 135(6):4201-3. PubMed ID: 4067313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
    Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
    Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.